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BACKGROUND: Obesity increases the risk of uterine cancer, but results by histological type have differed.
METHODS: We followed 36755 women for 17.8 years for uterine cancers.
RESULTS AND CONCLUSION: Body mass index (BMI) was positively associated with uterine cancers as a whole, particularly
for endometrioid adenocarcinomas, for which the relative risk for very obese women (BMI: X40kgm
 2) compared with lean
(BMI: 20–24kgm
 2) women, was 11.1 (95% confidence interval: 5.2–23.8).
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The obesity epidemic contributes to a steadily increasing incidence
of endometrial cancer for which obese women may have a six-fold
higher risk compared with lean women (Lindemann et al, 2008).
Most studies have assessed the effect on uterine cancers as a whole
(Tretli and Magnus, 1990; Jonsson et al, 2003; Bjorge et al, 2007) or
endometrial cancer without further differentiation (Brinton et al,
1992; Levi et al, 1992; Shu et al, 1992; Swanson et al, 1993; de
Waard et al, 1996; Goodman et al, 1997; Schouten et al, 2006;
Trentham-Dietz et al, 2006). However, it has been hypothesised
that the positive association of obesity may be restricted to
endometrioid adenocarcinomas, as this subtype appears to be
oestrogen dependent, and oestrogen is produced in the adipose
tissue (Siiteri, 1987; Azziz, 1989).
Two population-based studies have addressed the issue of whether
obesity is differentially associated with histological subtypes of
uterine cancer, but with inconsistent results. In one study, there was a
stronger positive association with endometrioid adenocarcinoma
(type I tumours) than for other subtypes (type II tumours, such as
papillary, serous and clear cell adenocarcinomas, and some poorly
differentiated carcinomas), as well as a weaker association for
sarcomas and mixed endothelial and mesenchymal tumours (Bjorge
et al, 2007). The other study differentiated between carcinoma and
sarcoma variants, and found increased risk associated with obesity
only for carcinomas (Tretli and Magnus, 1990).
In this prospective study of 36755 women, we have compared
the association of BMI with the risk of uterine cancer as a single
entity, with all endometrial cancers, and with the risk of
endometrioid adenocarcinomas.
MATERIALS AND METHODS
Between 1984 and 1986, all inhabitants aged 20 years and older in
the Nord-Trøndelag County in Norway were invited to participate
in a study (the HUNT-I Study), in which standardised measure-
ments of height and weight were made. A detailed description of
the HUNT Study is given elsewhere (Holmen et al, 1991). Among
the 38260 women who participated, we excluded 1088 with
prevalent cancer (except basal cell carcinoma) and 417 because
their body mass index (BMI) could not be calculated. Thus, 36755
women were followed up for cancer incidence.
Women diagnosed with cancer of the uterine corpus (Interna-
tional Classification of Diseases, 7th revision, ICD-7, code 172)
were identified by the linkage of HUNT Study participants to the
Norwegian Cancer Registry, using the unique 11-digit identity
number of Norwegian citizens. Follow-up time was calculated as
person-years from the HUNT baseline until the date of diagnosis of
uterine cancer or any other cancer (except basal cell carcinoma),
emigration, death or the end of follow-up, 31 December 2005,
whichever occurred first.
The histological diagnoses are based on mandatory reporting to
the Norwegian Cancer Registry from all pathological laboratories
in Norway. Cancers diagnosed before 1993 were classified
according to MOTNAC (Manual of Tumor Nomenclature and
Coding). After 1993, tumours were classified according to ICD-O-2,
a 6-digit code for morphology and grade of differentiation.
According to the WHO classification (WHO Classification of
Tumours, 2003), tumours were sub-classified as epithelial or
mesenchymal tumours. Endometrioid adenocarcinomas included
all variants (typical, villoglandular, with squamous differentiation,
secretory and ciliated), and moderately or well-differentiated
adenocarcinomas diagnosed before 1993.
Body mass index was calculated as weight divided by height
squared (kgm
 2), and categorised as o20, 20–24, 25–29, 30–34,
35–39 and 40kgm
 2 and higher. Information on prevalent
diabetes (yes/no) and smoking status (current, former, never,
missing) was obtained through self-administered baseline ques-
tionnaires. Information on recreational physical activity
(i.e., walking, skiing, swimming or other sports) included the
frequency (five categories), duration (four categories) and
intensity (three categories) of the activity.
Statistical analysis
We estimated age-adjusted relative risks (as hazard ratios)
associated with BMI for different categories of uterine cancer
using Cox regression analysis (SPSS statistical package, version
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y16.0, SPSS, Inc, Chicago, IL, USA). In three separate analyses, the
following classifications were used all uterine cancers, all endome-
trial cancers and endometrioid adenocarcinomas. To estimate the
log-linear trends of BMI, we included BMI as a continuous variable.
In a separate analysis, we assessed BMI and the risk of uterine
cancers other than endometrioid adenocarcinomas.
This study was approved by the Regional Committee for Ethics
in Medical Research and by the Norwegian Data Inspectorate.
RESULTS
We followed up 36755 women (mean age at baseline, 49 years) for
an average of 17.8 years (range: 0–21). During follow-up, 263
histologically verified uterine cancers were diagnosed, and 224 of
them (85%) were classified as endometrial cancers. Among the
latter, 166 (74%) were classified as endometrioid adenocarcinomas
(Table 1). In total 58 (26%) of the endometrial cancers were either
other epithelial tumours (n¼44/20%) or mesenchymal tumours
(n¼14/6%).
For uterine cancers as a whole, there was a strongly positive
association with BMI (P for trend, o0.001) that was also present
for endometrial cancers and for endometrioid adenocarcinomas
(P for trend, o0.001). The relative risks across the categories of
BMI were higher for endometrial cancers than for all uterine
cancers, but confidence intervals (CIs) overlapped. Compared with
the reference (BMI: 20–24kgm
 2), the age-adjusted relative risk
for BMI X40kgm
 2 was 8.3 (95% CI: 4.1–16.7) for endometrial
cancer, 6.7 (95% CI: 3.4–13.4) for all uterine cancers and 11.1 (95%
CI: 5.2–23.8) for endometrioid adenocarcinomas. For uterine
cancers other than endometrioid adenocarcinomas (n¼97),
compared with the reference group (BMI: 20–24), there was an
increased risk associated with a BMI of X35 (age-adjusted relative
risk 4.67 (95% CI: 2.4–9.2)), but there were no associations for the
other BMI categories.
Further adjustment for prevalent diabetes, smoking and physical
activity did not substantially influence the reported results (data
not shown).
DISCUSSION
In this prospective study of 36755 women, there was a strongly
positive and linear association of BMI with the risk of cancer of the
uterine corpus. Separate analyses showed that a stronger associa-
tion of BMI with the risk of endometrioid adenocarcinomas than
for uterine cancers as a whole. Previous studies have shown a two-
to six-fold higher risk of uterine cancer among obese women
compared with lean women. Most studies have used all uterine
cancers as a single entity as the endpoint (Jonsson et al, 2003;
Lindemann et al, 2008), or histologically verified endometrial
cancers without further differentiation (Levi et al, 1992; Shu et al,
1992; Swanson et al, 1993; de Waard et al, 1996; Goodman et al,
1997; Schouten et al, 2006; Trentham-Dietz et al, 2006). The results
related to the histological subtypes of uterine cancer have been
inconsistent; one study reported positive associations of BMI with
the risk of endometrioid adenocarcinomas (type I tumours) and
papillary, serous and clear cell adenocarcinomas, as well as
sarcomas and mixed tumours (Bjorge et al, 2007). The other study
distinguished between carcinomas and sarcomas, and found that
BMI was positively associated only with uterine carcinomas (Tretli
and Magnus, 1990).
A weakness of our study is the incomplete histological
classification of endometrial cancer subtypes before 1993 when
the classification of uterine cancer in the Norwegian Cancer
Registry was changed, allowing more refined analyses. Thus, 111
(64%) of the endometrioid adenocarcinomas were diagnosed after
1993, when the classification distinctly differentiated between type
I, type II and other tumours of the endometrium. In our study,
74% (n¼166) of all endometrial cancers were classified as
endometrioid adenocarcinomas, which accords with the literature
(Sherman, 2000). Another limitation is the lack of control for
reproductive factors, such as parity, the use of oral contraceptives
and postmenopausal hormone therapy. Generally, Norwegian
women were restrictive in their use of hormone therapy in the
1980s, but this subsequently increased to B35% of women in their
postmenopausal stage in the 1990s. However, the use of combined
oestrogen–progesterone preparations, which constituted 70% of
the medication, has not been associated with increased risk of
endometrial cancer in Norway (Bakken et al, 2004).
The increased risk associated with obesity has been attributed
to higher concentrations of endogenous oestrogen hormones.
Oestrogens produced in the adipose tissue have a direct mitogenic
effect on endometrial cells, and it is assumed that this effect is
not counterbalanced by progesterone because of chronic anovula-
tion accompanied by reduced progesterone synthesis. However,
weight-related increase in endometrial growth factors (Pasquali
et al, 1997), cytokines (i.e., leptin, adiponectin) (Petridou
et al, 2002; Housa et al, 2006) or transcription factors may be
related to the development of uterine tumours (Roberts-Thomson,
2000).
Our results suggest a positive association of BMI with
all subtypes of uterine cancer, but the association was
strongest for endometrioid adenocarcinomas. However,
the moderate precision of the estimates warrants that future
studies assess how obesity is related to different subtypes of
uterine cancer.
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Table 1 Relative risk (RR) of cancer of the uterine corpus according to histological subtype in the study population of 36755 women in Norway
Uterine cancers (n¼263) Endometrial cancers (n¼224) Endometrioid adenocarcinomas (n¼166)
Variable No. of persons RR
a 95% CI P for trend RR
a 95% CI P for trend RR
a 95% CI P for trend
BMI
o20 3065 0.7 0.3–1.5 0.6 0.2–1.5 0.8 0.3–1.9
X20–24 17967 1.0 1.0 1.0
X25–29 10820 1.6 1.2–2.2 1.8 1.3–2.4 2.1 1.4–3.0
X30–34 3685 2.0 1.3–2.9 2.1 1.4–3.2 2.1 1.3–3.5
X35–39 972 5.3 3.4–8.2 5.6 3.5–9.1 5.8 3.3–10.3
X40 246 6.7 3.4–13.4 o0.001 8.3 4.1–16.7 o0.001 11.1 5.2–23.8 o0.001
BMI¼body mass index; CI¼confidence interval.
aAdjusted for age in 10-year categories (o30, 30–39, 40–49, 50–59, 60–69, X70).
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